Background
==========

Gastric cancer (GC) is one of the most aggressive malignancies with poor prognosis [@B1]. The prevalence of GC in China is amongst the highest in the world, along with Japan and Korea [@B1],[@B2]. Despite recent advances in diagnostic and therapeutic strategies, the prognosis of GC patients remains poor due to tumor recurrence and metastasis.

Cancer stem cells (CSCs), defined as a small subpopulation of cancer cells with the ability of self-renewal and pluripotency, may account for tumor progression, metastasis and recurrence after therapy [@B3]-[@B5]. Recent data suggest that CSCs rely on a specialized tumor microenvironment (TME) or niche [@B6]. However, the effect of TME on cancer cell stemness remains unclear on GC. Tumor-associated macrophages (TAMs), the most abundant immune-related stromal cells in TME [@B7], are pivotal orchestrators of TME and directly affect cancer cell growth, neoangiogenesis, and extracellular matrix remodeling [@B8]. TAMs of GC often display an alternatively activated phenotype, promoting tumor invasion and metastasis, and are associated with poor prognosis in cancer patients [@B9]-[@B11].

There have been few studies on the correlation between infiltration of TAMs and expression of CSCs markers in GC, and little is known on how TAMs affect CSCs properties in GC. We speculated that TAMs might induce cancer cell stemness and consequently promote GC recurrence and metastasis. The purpose of the present study was to examine the correlation of infiltrated polarized CD163+ TAMs with expression of CSCs markers in GC tumors, using immunohistochemistry (IHC). The clinicopathological characteristics of GC, recurrence patterns, risk factors to predict recurrence and prognosis were all analyzed.

Materials and Methods
=====================

Patients and Specimens
----------------------

This study included consecutive 236 patients with histologically confirmed primary GC, all of whom underwent radical gastrectomy with curative intend between 2007 and 2009 at the Nanjing Drum Tower Hospital and the 101th Hospital of People Liberation Army. They included 150 men and 86 women, ranging from 20 to 84 years of age (mean, 57.8 years). Patients lost during follow up were excluded. All specimens were pathologically reassessed independently by two gastrointestinal pathologists, according to the WHO criteria [@B12]. None of the patients received neoadjuvant or adjuvant chemotherapy before the operation.

This retrospective study protocol was approved by the clinical research ethics committee of the Nanjing Drum Tower Hospital and the 101th Hospital which complies with the Declaration of Helsinki.

Immunohistochemistry
--------------------

All specimens were fixed in 10% buffered neutral formalin, embedded in paraffin wax, and cut into 4-μm-thick sections. After deparaffinization in xylene and rehydration in a graded series of ethanol, the sections were washed twice (5 min per wash) in phosphate buffered saline (PBS). Endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 15 min. After washing in PBS, the slides were heated at 120°C in an autoclave for 10 min for antigen retrieval. A nonspecific staining blocking agent (Dako, Kyoto, Japan) was used to prevent nonspecific binding. Slides were incubated with the mouse monoclonal anti-CD163 antibody and monoclonal antibodies against CSCs markers, CD133 and CD44, overnight at 4°C, and washed in PBS for 10 min. The information on antibody manufacturers, clones and concentrations was listed in Table [1](#T1){ref-type="table"}. Subsequently, the slides were treated with a biotinylated secondary antibody for 10 min at room temperature. After washing in PBS, the slides were reacted with 3-3\'-diamino-benzidine (DAB) solution for 5 min and counterstained with hematoxylin. Positive controls consisted of each staining run and consisted of GCs known to express each of the antigens. Negative controls were normal mouse serum instead of the primary antibody.

Evaluation of Immunohistochemical Staining
------------------------------------------

All slices were independently evaluated by two pathologists who were blinded to the clinical data. The percentage of immunoreactive cells was scored on a scale of 0 to 4 from no staining as 0, 1 to 10% of cells stained as score 1, 11 to 50% as 2, 51 to 80% as 3, and 81 to 100% as 4. The staining intensities were graded from 0 as negative, to 1 as weak, 2 as moderate, and 3 as strong, respectively. The final immunohistochemical score (IHS) was obtained by calculating the product of the staining intensity and the positive cell percentage. Cases with a score of less than 5 were considered as low expression, and those with ≥6 were regarded as high expression.

Stained sections were microscopically scrutinized at ×200 magnification. TAMs density identified by CD163 expression were estimated (per mm^2^) at ×400 magnification in 5 fields per case. The average number of positive cells in each case was determined. Low density was defined as the number of positive cells smaller than the average; otherwise, high density was considered.

Follow-up
---------

All GC patients underwent radical gastrectomy with nodal dissection. No major perioperative complications occurred in GC patients who were all discharged home after a short hospital stain period. The closing date for follow-up was January 31, 2016. All patients were followed up every 3 months during the first 2 years after discharge and every 6 months thereafter. GC recurrence was confirmed by detection of significantly increased levels of tumor seral biomarkers, including Carcinoembryonic antigen (CEA), Alpha Fetal Protein (AFP), CA19-9 and CA125, and imaging detection of tumor in distant organs by chest X-Ray, barium meal, abdominal ultrasonography (US), computed tomography (CT), and upper endoscopy, during the follow-up period. The locations and times of tumor recurrence were recorded. The follow-up time was calculated from the day of surgery to the day of detection of tumor recurrence or death. Overall survival (OS) was defined as the interval between surgery and last visit or death of any causes. Disease-free survival was measured in patients in whom a tumor was present and calculated as the time from end of treatment to date at which recurrence was detected or most recent follow-up in which recurrence was not detected (censored).

Statistical Analysis
--------------------

All statistical analyses were performed with SPSS software, version 17.0 (SPSS Inc., Chicago, IL, USA). The correction between expression of CD163, CD44 and CD133 and clinicopathological features was analyzed by the χ^2^ and Fisher\'s exact tests. The Spear-man\'s rank correlation coefficient was used for analyzing the association of CD133 and CD44 expression levels with CD163 expression levels. Post-operative survival curves were estimated using the Kaplan-Meier method with the log-rank test. For multivariate analysis, the prognostic factors were analyzed using the Cox\'s proportional hazard model. Overall and disease-specific survivals were the designated endpoints. Differences with a p value of 0.05 or less were considered statistically significant.

Results
=======

Patient Characteristics
-----------------------

The detailed clinicopathological characteristics of GC patients after resection were shown in Table [2](#T2){ref-type="table"}. The median follow-up period after surgery was 33.14 months. When the follow-up was over, 86 patients were alive without recurrence and additional 12 with GC recurrence, while 138 were dead (63 died of other diseases without recurrence and 75 deceased due to tumor recurrence). The mean OS of 236 patients was 39.42±19.68 months, and the 5-year survival rate of all enrolled patients was 22.4%.

Infiltration of TAMs and Association with Clinicopathologic Features of Tumors
------------------------------------------------------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, expression of CD163 in GC was significantly higher than that in the adjacent benign gastric mucosa. Immunoreactivity of CD44 was observed primarily in the cytoplasm and membrane of tumor cells, but weak or negative in the majority of gastric mucosa (Fig. [1](#F1){ref-type="fig"}). CD133 stained the membrane of tumor cells, but was negative for most gastric mucosa (Fig. [1](#F1){ref-type="fig"}). High expression of CD163 was found in 67.8% (59/87) of GC cases with recurrence, significantly higher than that without recurrence (47.0%, 70/149). CD163 expression was significantly related to the TNM stage, nodal metastasis, the depth of invasion, tumor differentiation, size, lymphovascular invasion, but not to the patient age, gender, tumor Lauren type, Borrmann type, location, and serum levels of CEA (Table [2](#T2){ref-type="table"}).

As shown in Table [3](#T3){ref-type="table"}, high expressions of CD163 was significantly associated with poor differentiation, large size, deep invasion depth, advanced TNM stage, node metastasis, lymphovascular invasion; expression of CSCs markers was significantly more frequently associated with overall recurrence, whereas patient age, gender, tumor histological type, location, Borrmann type, and serum levels of CEA level were.

Time to Recurrence and Recurrence Patterns
------------------------------------------

Tumor recurrence occurred in 87 (36.8%) patients, most (53, 60.9%) within 2 years. The median time to recurrence was 18.0 months (range, 6 - 78). Various recurrence patterns were noted, including peritoneal relapse (31, 35.6%), hematogeneous spread (28, 31.5%) to the liver (n=15), lung (n=7), bone (n=5), and brain (n=1). Locoregional recurrence was found in 18 (20.7%), distant lymph node metastasis in 5 (5.7%), and combined patterns in 5 (5.7%) (Figure [2](#F2){ref-type="fig"}).

Association of TAMs with Expression of Cancer Stem Cell Markers
---------------------------------------------------------------

As shown in Table [4](#T4){ref-type="table"}, high expression of neoplastic cells in GC were found in over half cases for CD44 (58.5%, 138/236) and CD133 (55.1%, 130/236). There existed a significant correlation between high expression of CD163 with high expression of CD44 (*r*=0.303, *P*\<0.001), and CD133 (*r*=273, *P*\<0.001).

Prognostic value of TAM Infiltration in Patients with Recurrent Gastric Carcinoma
---------------------------------------------------------------------------------

As shown in the Kaplan-Meier survival curves (Figure [3](#F3){ref-type="fig"}A-B, Table [5](#T5){ref-type="table"}), overall DSS and OS rates for the cohort were 56.6% and 41.5%, respectively, which were significantly shorter for patients with high CD163 expression than those with low CD163 expression (Figures [3](#F3){ref-type="fig"}A and 3B). High expression of cancer stem cell markers, CD44 and CD133, was also statistically correlated with poor OS (*P*\<0.05) (Figure [3](#F3){ref-type="fig"}C-D). Moreover, as exhibited in Table [4](#T4){ref-type="table"}, multivariate Cox analysis showed that high expression of CD163 and over-expression of CD44 were independent worse prognostic factors for DSS and OS rates in GC patients with recurrence (*P*\<0.05). Compared with GC patients without recurrence, DSS and OS rates for patients with recurrence were significantly lower (*P*\<0.001) (Figures [3](#F3){ref-type="fig"}E). In patients with recurrence, high-expression of CD163 was significantly correlated with poor survival (Figures [3](#F3){ref-type="fig"}F) (*P*\<0.001), and TAM infiltration was a worse prognostic factor.

Discussion
==========

The CSC hypothesis contributes to tumorigenesis, metastasis and recurrence following therapy [@B13]. A number of studies have been focused on CSCs and their niche because signaling from the niche regulates CSC function [@B14]. Recent reports show that TAMs play a key role in maintaining the undifferentiated state of CSCs and promote cancer progression [@B15]. Targeting or reprogramming TAMs can inhibit cancer progression and metastasis, and may represent a promising target of cancer treatment [@B16], [@B17]. TAMs may migrate along lymphatic channels to pre-metastatic lymph nodes [@B10]. High levels of infiltrating TAMs were associated with poor prognosis and may be involved in the epithelial-mesenchymal transition phenomenon in human GC [@B9]. Infiltration of polarized TAMs has been identified as an independent prognostic factor, which, along with the TNM stage, may refine a more precise prognosis stratification system [@B11].

The results from the present study supported the hypothesis that infiltration of CD163+TAMs correlates with aberrant expressions of CSCs markers, predicts worse OS of patients with recurrent GC. Multivariate analysis confirmed that the polarized TAMs emerged as an independent risk factor for GC recurrence, and also an independent worse prognostic factor for GC patients, especially for those with recurrence. High expression of CSC markers, CD44 and CD133, is also significantly associated with GC recurrence and may be used as a useful risk prediction marker for GC recurrence, if confirmed by futures studies with larger samples [@B18], [@B19].

In the current study, high levels of TAM infiltration was found in over half GC patients and also as an independent poor prognostic factor, significantly associated with aggressive characteristics of cancer. Overexpression of CD163 in TAMs was positively correlated with high expressions of CSC markers, CD44 and CD133 and predicted GC recurrence and poor prognosis when combined with with CD44 expression, suggesting that CSCs in GC may function as a promoter for tumor progression and aggressiveness, and polarized CD163+TAMs may help maintain CSCs in GC tumor. If confirmed by future studies in larger samples, the results may be useful in GC patient management.

In a recent meta-analysis, Liu et al concluded that TAMs was not an independent predictor for worse survival of GC patients on the basis of analysis of 11 published papers [@B20]. In that paper, the sample size remains small and importantly, the most important recent paper by Zhang J, et al. was not included [@B9]. In that study by Zhang et al, the findings suggested that the high level of infiltration TAMs was associated with aggressive features of GC and was an independent poor prognostic factor in GC patients. In addition, publication bias may impact the reliability of the analysis results. Regardless, further prospective, clinical and basic researches are needed to elucidate the prognostic significance and molecular mechanism of TAMs in GC patients.

In our series, there are large variations in tumor size, differentiation, lymph node metastasis, lymphovascular invasion, and TNM stage between the GC group with recurrence and that without. By multivariant analysis, patients presenting at more advanced TNM stages, coupled with high expression of CD163 along with CD44 and CD133 most frequently had GC recurrence, which showed in three main patterns: locoregional, peritoneal, and hematogeneous metastases. Peritoneal relapse and hematogeneous metastases appear to be the predominant patterns and account for most recurrences, which is similar to those reported previously [@B21], [@B22].

GC patient survivals after recurrence have rarely been documented in previous studies [@B23], [@B24]. In our previously study, the majority of GC patients with early recurrence (within two years) died within two years, and CD44 was an independent predictor of early recurrence [@B25]. The results of this study, consistent with the data of our previously study, demonstrated that GC patients with recurrence, especially for those with high-expression of CD163, had a significant correlation with poor survival (*P*\<0.005).

Our data have several limitations. First, our definition of polarized TAMs by using CD163 was limited because macrophages display high plasticity in response to different stimuli, such as cytokines and easily change their phenotype, which should be assessed using reliable surface markers [@B26]. Second, this was a retrospective study with a limited sample size. Finally, we did not study the detailed molecular mechanisms on how TAMs affect GC progression and recurrence.

In conclusion, high infiltration of TAMs was associated with high expression of CSC markers in GC, and related to aggressive behavior, including recurrence. Polarized CD163+TAMs emerged as an independent risk factor for recurrence and worse prognosis for GC patients, especially for those with recurrence.
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###### 

The list of manufacturers, origin, clones and concentrations of the antibodies.

  Parameters            Manufacturer                Origin   Clone        Concentration
  --------------------- --------------------------- -------- ------------ ---------------
  Anti-CD163 antibody   Abcam, Cambridge, MA, USA   Mouse    mono-clone   1: 100
  Anti-CD44 antibody    Abcam, Cambridge, MA, USA   Mouse    mono-clone   1: 100
  Anti-CD133 antibody   Abcam, Cambridge, MA, USA   Mouse    mono-clone   1: 100

###### 

The relationship between expression of CD163 expression and clinicopathological features of gastric cancer.

  Parameters                N     High CD163 positive (%)   χ^2^-value   *P*value
  ------------------------- ----- ------------------------- ------------ -----------
  Age(yr)                                                   2.097        0.148
  \<60                      129   65 (50.4)                              
  ≥60                       107   64 (59.8)                              
  Gender                                                    0.929        0.335
  Male                      151   79 (52.3)                              
  Female                    85    50 (58.8)                              
  Tumor location                                            0.752        0.861
  Upper third               43    23 (53.5)                              
  Middle third              54    29 (53.7)                              
  Lower third               122   66 (54.1)                              
  Diffused                  17    11 (64.7)                              
  Differentiation                                           4.734        **0.030**
  Well/Moderate             86    39 (45.3)                              
  Poor                      150   90 (60.0)                              
  Lauren type                                               0.311        0.577
  Intestinal                110   58 (52.7)                              
  Diffuse                   126   71 (56.3)                              
  Tumor size(cm)                                            4.623        **0.032**
  \<5                       99    46 (46.5)                              
  ≥5                        137   83 (60.6)                              
  Borrmann type                                             3.755        0.289
  Ⅰ                         8     3 (37.5)                               
  Ⅱ                         49    22 (44.9)                              
  Ⅲ                         103   59(57.3)                               
  Ⅳ                         76    45 (59.2)                              
  Depth of invasion                                         14.577       **0.002**
  pT1                       15    3 (20.0)                               
  pT2                       35    13 (37.1)                              
  pT3                       88    52 (59.1)                              
  pT4                       98    61 (62.2)                              
  Lymph node status                                         5.089        **0.024**
  N0/N1                     77    34 (44.2)                              
  N2/N3                     159   95 (59.7)                              
  Vascular invasion                                         4.408        **0.036**
  Absent                    74    33 (44.6)                              
  Present                   162   96 (59.3)                              
  Recurrence                                                11.377       **0.001**
  Absent                    149   69 (46.3)                              
  Present                   87    60 (69.0)                              
  TNM stage                                                 5.814        **0.016**
  Ⅰ-Ⅱ                       80    35 (43.75)                             
  Ⅲ-Ⅳ                       156   94 (60.3)                              
  Serum CEA level (μg /L)                                   1.956        0.162
  \<5                       90    44 (48.9)                              
  ≥5                        146   85 (58.2)                              

###### 

Characteristics of gastric cancer with recurrence compared with patients without recurrence.

  ---------------------------------------------------------------------------------
  Parameters                Recurrence\   No recurrence\   χ^2^-value   *P*value
                            (n=87)        (n=149)                       
  ------------------------- ------------- ---------------- ------------ -----------
  Age(yr)                                                  3.157        0.076

  \<60                      41            88                            

  ≥60                       46            61                            

  Gender                                                   0.561        0.454

  Male                      53            98                            

  Female                    34            51                            

  Tumor location                                           2.732        0.435

  Upper third               19            24                            

  Middle third              22            32                            

  Lower third               39            83                            

  Diffused                  7             10                            

  Differentiation                                          4.664        **0.031**

  Well/Moderate             24            62                            

  Poor                      63            87                            

  Lauren type                                              0.015        0.903

  Intestinal                41            69                            

  Diffuse                   46            80                            

  Tumor size(cm)                                           4.201        **0.040**

  \<5                       29            70                            

  ≥5                        58            79                            

  Borrmann type                                            2.664        0.508

  Ⅰ                         2             6                             

  Ⅱ                         14            35                            

  Ⅲ                         42            61                            

  Ⅳ                         29            47                            

  Depth of invasion                                        6.030        0.110

  pT1                       2             13                            

  pT2                       12            23                            

  pT3                       30            58                            

  pT4                       43            55                            

  Lymph node status                                        8.933        **0.003**

  N0/N1                     18            59                            

  N2/N3                     69            90                            

  Vascular invasion                                        4.482        **0.034**

  Absent                    20            54                            

  Present                   67            95                            

  TNM stage                                                10.729       **0.001**

  Ⅰ-Ⅱ                       18            62                            

  Ⅲ-Ⅳ                       69            87                            

  CD163                                                    9.622        **0.002**

  Low                       28            79                            

  High                      59            70                            

  CD44                                                     6.246        **0.012**

  Low                       27            71                            

  High                      60            78                            

  CD133                                                    9.028        **0.003**

  Low                       28            78                            

  High                      59            71                            

  Serum CEA level (μg /L)                                  1.127        0.288

  \<5                       37            53                            

  ≥5                        50            96                            
  ---------------------------------------------------------------------------------

###### 

The association between CD163 with CSCs markers: CD44 and CD133.

          CD163   *r*   *P*     
  ------- ------- ----- ------- -------------
  CD44                  0.303   **\<0.001**
  Low     62      36            
  High    45      93            
  CD133                 0.273   **\<0.001**
  Low     64      42            
  High    43      87            

###### 

Multivariate analysis of significant prognostic factors for disease-specific and overall survivals in patients with gastric cancer.

  Parameters                  Hazard ratio   95% CI         *P*value
  --------------------------- -------------- -------------- ----------
  Disease-specific survival                                 
  TNM stage                   5.359          2.700-10.636   \<0.001
  CD163                       3.318          1.304-8.442    0.007
  CD44                        1.778          1.048-3.017    0.026
  Lymph node status           1.708          1.066-2.738    0.033
  Overall survival                                          
  TNM stage                   3.087          1.264-7.538    0.001
  CD163                       2.643          1.637-4.269    0.003
  CD44                        1.806          1.277-2.555    0.014

###### 

Multivariate analysis of significant prognostic factors for overall survival in patients with recurrent gastric cancer.

  Parameters   Hazard ratio   95% CI        *P*value
  ------------ -------------- ------------- ----------
  TNM stage    1.549          1.049-2.288   0.043
  CD163        2.609          1.282-5.310   0.024
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